» Articles » PMID: 22782694

MRSA Decolonization: Success Rate, Risk Factors for Failure and Optimal Duration of Follow-up

Overview
Journal Infection
Date 2012 Jul 12
PMID 22782694
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) decolonization is a widely established, though controversial part of many MRSA controlling strategies. The aim of this study was to evaluate our decolonization success rate, identify the risk factors for decolonization failure and determine the optimal duration of follow-up in our low MRSA prevalence setting (2.6 % of isolates).

Methods: Every patient with newly detected MRSA colonization or infection between January 2007 and December 2009 was recruited to the study. The MRSA strategy of our institution (a 700 bed tertiary hospital in eastern Switzerland) consists of a 5-day regimen of nasal mupirocin ointment, chlorhexidin mouth rinse and whole body wash with didecyldimonium chloride. Systemic antibiotics are usually not added to the regimen.

Results: We determined a MRSA decolonization success rate of 65 % (33/51) after a median follow-up of 13 months [i.e. a tripling of the spontaneous clearance rate of 22 % (6/27) in the non-decolonized group]. The most important risk factor for decolonization failure was colonization of the respiratory tract [odds risk (OR) 9.1, 95 % confidence interval (CI) 1.2-66.7], as well as isolation of MRSA spa-type 002 ([R 5.8, 95 % CI 1.0-33.3). Of all the episodes of MRSA recurrence, 88 % (14/16) were detected within 270 days after decolonization.

Conclusion: High MRSA decolonization success rates can be achieved without the routine use of oral antibiotics. A time period of 1 year after decolonization seems to be a reasonable duration of follow-up in our setting. We encourage other institutions to take into account local MRSA epidemiology (e.g. predominance of certain subtypes) for the management of MRSA patients.

Citing Articles

Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and in Intensive Care Units: A Pragmatic Resume including Pathogens R and a Cost-Effectiveness Analysis.

Fanelli C, Pistidda L, Terragni P, Pasero D Antibiotics (Basel). 2024; 13(8).

PMID: 39200090 PMC: 11351734. DOI: 10.3390/antibiotics13080789.


Methicillin-Resistant in the Oral Cavity: Implications for Antibiotic Prophylaxis and Surveillance.

Donkor E, Kotey F Infect Dis (Auckl). 2021; 13:1178633720976581.

PMID: 33402829 PMC: 7739134. DOI: 10.1177/1178633720976581.


Prevalence of Staphylococcus aureus colonization in patients for total joint arthroplasty in South Africa.

Pietrzak J, Maharaj Z, Mokete L J Orthop Surg Res. 2020; 15(1):123.

PMID: 32238194 PMC: 7110725. DOI: 10.1186/s13018-020-01635-4.


Impact of Mobility on Methicillin-Resistant among Injection Drug Users.

Agusto F, Kim S Antibiotics (Basel). 2019; 8(2).

PMID: 31212943 PMC: 6628130. DOI: 10.3390/antibiotics8020081.


Impact of Decolonization Protocols and Recurrence in Pediatric MRSA Skin and Soft-Tissue Infections.

Papastefan S, Buonpane C, Ares G, Benyamen B, Helenowski I, Hunter C J Surg Res. 2019; 242:70-77.

PMID: 31071607 PMC: 6682437. DOI: 10.1016/j.jss.2019.04.040.


References
1.
Larsson A, Gustafsson E, Nilsson A, Odenholt I, Ringberg H, Melander E . Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis. 2011; 43(6-7):456-62. DOI: 10.3109/00365548.2011.562530. View

2.
Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C . A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999; 18(7):461-6. DOI: 10.1007/s100960050324. View

3.
Marschall J, Muhlemann K . Duration of methicillin-resistant Staphylococcus aureus carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol. 2006; 27(11):1206-12. DOI: 10.1086/507917. View

4.
Simor A, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin H . Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2006; 44(2):178-85. DOI: 10.1086/510392. View

5.
Brown D, Edwards D, Hawkey P, Morrison D, Ridgway G, Towner K . Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother. 2005; 56(6):1000-18. DOI: 10.1093/jac/dki372. View